Literature DB >> 20549322

Atherosclerotic plaque regression: fact or fiction?

Nesan Shanmugam1, Ana Román-Rego, Peter Ong, Juan Carlos Kaski.   

Abstract

Coronary artery disease is the major cause of death in the western world. The formation and rapid progression of atheromatous plaques can lead to serious cardiovascular events in patients with atherosclerosis. The better understanding, in recent years, of the mechanisms leading to atheromatous plaque growth and disruption and the availability of powerful HMG CoA-reductase inhibitors (statins) has permitted the consideration of plaque regression as a realistic therapeutic goal. This article reviews the existing evidence underpinning current therapeutic strategies aimed at achieving atherosclerotic plaque regression. In this review we also discuss imaging modalities for the assessment of plaque regression, predictors of regression and whether plaque regression is associated with a survival benefit.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20549322     DOI: 10.1007/s10557-010-6241-0

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  9 in total

1.  Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke.

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Vijay K Sharma; Christos Krogias; Robert Mikulik; Konstantinos Vadikolias; Milija Mijajlovic; Apostolos Safouris; Christina Zompola; Simon Faissner; Viktor Weiss; Sotirios Giannopoulos; Spyros Vasdekis; Efstathios Boviatsis; Anne W Alexandrov; Konstantinos Voumvourakis; Andrei V Alexandrov
Journal:  Neurology       Date:  2016-02-24       Impact factor: 9.910

2.  Hyperglycemia impairs atherosclerosis regression in mice.

Authors:  Nathalie Gaudreault; Nikit Kumar; Victor R Olivas; Delphine Eberlé; Kyle Stephens; Robert L Raffai
Journal:  Am J Pathol       Date:  2013-10-08       Impact factor: 4.307

3.  Treating cardiovascular atherosclerotic plaques with Tongmaijiangzhi (TMJZ) capsule.

Authors:  Hong-Qiang Ren; Li Zhao; Zhong Shuang Zhang; Zhong Wang; Li Wang; Jun Cang Duan; Li Li; Zhi Hong Zhai; De Tao Qu; Hui Huang
Journal:  Afr J Tradit Complement Altern Med       Date:  2013-10-03

Review 4.  Is atherosclerosis regression a realistic goal of statin therapy and what does that mean?

Authors:  Mukesh Singh; Updesh Singh Bedi
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

5.  Neovascularization of coronary tunica intima (DIT) is the cause of coronary atherosclerosis. Lipoproteins invade coronary intima via neovascularization from adventitial vasa vasorum, but not from the arterial lumen: a hypothesis.

Authors:  Vladimir M Subbotin
Journal:  Theor Biol Med Model       Date:  2012-04-10       Impact factor: 2.432

6.  Arterial pathology in canine mucopolysaccharidosis-I and response to therapy.

Authors:  Jeremiah A Lyons; Patricia I Dickson; Jonathan S Wall; Merry B Passage; N Matthew Ellinwood; Emil D Kakkis; Michael F McEntee
Journal:  Lab Invest       Date:  2011-03-07       Impact factor: 5.662

7.  Poor maternal nutrition programmes a pro-atherosclerotic phenotype in ApoE-/- mice.

Authors:  Heather L Blackmore; Ana V Piekarz; Denise S Fernandez-Twinn; John R Mercer; Nichola Figg; Martin Bennett; Susan E Ozanne
Journal:  Clin Sci (Lond)       Date:  2012-08-01       Impact factor: 6.124

8.  Long-term exposure to traffic-related air pollution and progression of carotid artery atherosclerosis: a prospective cohort study.

Authors:  Wen Qi Gan; Ryan W Allen; Michael Brauer; Hugh W Davies; G B John Mancini; Scott A Lear
Journal:  BMJ Open       Date:  2014-04-07       Impact factor: 2.692

9.  Effect of dietary supplement from mono-culture fermentation of Moringa oleifera seeds by Rhizopus stolonifer on hematology and markers linked to hypercholesterolemia in rat model.

Authors:  Majekodunmi R Adedayo; Jacob K Akintunde; Alhassan Sani; Aline A Boligon
Journal:  Food Sci Nutr       Date:  2018-08-14       Impact factor: 2.863

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.